Vanguard Group Inc. Increases Stake in Tempus AI, Inc. $TEM

Vanguard Group Inc. boosted its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 8.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,258,621 shares of the company’s stock after acquiring an additional 817,014 shares during the quarter. Vanguard Group Inc. owned 0.06% of Tempus AI worth $605,772,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI in the third quarter valued at approximately $26,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Tempus AI in the third quarter worth approximately $38,000. Lodestone Wealth Management LLC acquired a new position in Tempus AI during the fourth quarter worth $42,000. Tsfg LLC grew its holdings in Tempus AI by 1,515.2% in the 3rd quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after buying an additional 500 shares in the last quarter. Finally, Cloud Capital Management LLC purchased a new stake in shares of Tempus AI in the third quarter valued at about $44,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Named to TIME’s 2026 list and expanded clinical reach via a multi?year collaboration with Keck/USC — boosts brand credibility, supports commercial adoption of Tempus’ AI precision?medicine tools and expands addressable clinical volume (coverage cites TIME recognition and the Keck Medicine partnership). TIME recognition article Keck partnership article
• Positive Sentiment: Investor?day visibility and bullish coverage — upcoming Investor Day (management roadmap) and fresh bull writeups may attract momentum buyers and reduce execution uncertainty if management delivers concrete commercialization milestones. Investor day / bull case coverage
• Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre?arranged Rule 10b5?1 plan — provides liquidity/estate planning context but can be interpreted variably by the market; sale was disclosed in an SEC filing. SEC Form 4 disclosure
• Neutral Sentiment: Analyst/valuation mix — some firms trimmed fair?value slightly and note the recent rally may be a short?term bounce; coverage is polarized (buy/hold/sell), so flows depend on upcoming execution/metrics. Analyst narrative article
• Negative Sentiment: Class action litigation over genetic data collection in an acquisition — proposed suits raise legal, compliance and remediation cost risk that can pressure sentiment until resolved. Class action article
• Negative Sentiment: Peer comparisons favor Illumina (ILMN) on valuation and earnings outlook — could divert institutional allocation away from TEM if investors prefer a more established genomics exposure. Peer comparison article

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. decreased their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research note on Wednesday, February 25th. Robert W. Baird began coverage on Tempus AI in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price target on the stock. HC Wainwright increased their price target on Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Finally, Mizuho assumed coverage on Tempus AI in a report on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $71.36.

Tempus AI Trading Up 0.0%

TEM opened at $55.02 on Monday. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32. The company has a market cap of $9.84 billion, a P/E ratio of -39.02 and a beta of 4.00. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The business’s 50-day simple moving average is $50.65 and its 200-day simple moving average is $63.17.

Insider Activity

In related news, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total transaction of $562,445.52. Following the transaction, the executive vice president owned 79,816 shares in the company, valued at $4,743,464.88. This trade represents a 10.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James William Rogers sold 10,084 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $595,460.20. Following the transaction, the chief financial officer owned 101,166 shares in the company, valued at $5,973,852.30. This represents a 9.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 563,471 shares of company stock worth $29,837,342 over the last ninety days. 24.26% of the stock is owned by corporate insiders.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.